80%Confidence
0Views
FDASource
2026-04-06Date
Summary
Rising Pharma's Temozolomide stability failure suggests potential quality issues in oncology drug manufacturing that could affect critical cancer treatment supplies. This may trigger increased FDA monitoring of Rising's manufacturing partners and stability testing protocols.
Actionable: Monitor Temozolomide supply availability and consider qualifying alternative manufacturers for this essential oncology medication.
AI Confidence: 80%
Data Points
firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now